Mylotarg Now Approved for the Treatment of Patients with CD33-Positive AML

JHOP Web Exclusives - FDA Approvals, News & Updates, Online Only

On September 1, 2017, the FDA approved gemtuzumab ozogamicin (Mylotarg; Pfi­zer) for the treatment of adults with newly diagnosed CD33-positive acute myeloid leukemia (AML), as well as patients aged ≥2 years with relapsed or refractory CD33-positive AML. It is approved as an orphan drug for this indication.

Gemtuzumab ozogamicin was originally approved in 2000 as monotherapy for older patients with relapsed, CD33-positive AML. However, after confirmatory trials failed to verify the drug’s clinical benefits and raised concerns about early death, the manufacturer voluntarily withdrew the drug from the market. The new FDA approval for gem­tuzumab ozogamicin is based on a lower recommended dose and a new dosing schedule (in combination with chemotherapy or as monotherapy), and includes a new patient population.

“We are approving Mylotarg after a careful review of the new dosing regimen, which has shown that the benefits of this treatment outweigh the risk. Mylotarg’s history underscores the importance of examining alternative dosing, scheduling, and administration of therapies for patients with cancer, especially in those who may be most vulnerable to the side effects of treatment,” said Richard Pazdur, MD, Director of the FDA’s Oncology Center of Excellence.

The FDA approval was based on 3 clinical trials. One study included 271 patients with newly diagnosed CD33-positive AML who were randomized to gemtuzumab ozogamicin, with or without chemotherapy. The event-free survival was 17.3 months with gemtuzumab ozogamicin alone versus 9.5 months with gemtuzumab ozogamicin plus chemotherapy.

The second study included 237 patients with newly diagnosed AML and compared gemtuzumab ozogamicin with best supportive care; the median overall survival was 4.9 months with gemtuzumab ozogamicin versus 3.6 months with best supportive therapy. The third study included 57 patients with relapsed, CD33-positive AML; of these, 26% of the patients achieved complete remission lasting a median of 11.6 months.

The common side effects reported with gemtuzumab ozogamicin include pyrexia, nausea, infection, vomiting, hemorrhage, thrombocytopenia, stomatitis, constipation, rash, headache, elevated liver function, and neutropenia. Severe side effects include low blood counts, infections, liver damage, hepatic veno-occlusive disease (VOD), infusion-related reactions, and hemorrhage. Gemtuzumab ozogamicin was approved with a boxed warning about the risk for severe or fatal hepatotoxicity, including VOD or sinusoidal obstruction syndrome. Pregnant women should not use this drug

Related Items
A Dynamic FDA Has Led to More Rapid Cancer Drug Development
Wayne Kuznar
JHOP Web Exclusives published on July 17, 2018 in FDA Approvals, News & Updates
FDA News - May 2018
TON - May 2018, Vol 11, No 2 published on May 15, 2018 in FDA Approvals, News & Updates
Welcome to the Third Annual Oncology Guide to New FDA Approvals
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Approvals, News & Updates
FDA Approvals in 2017 Represent a 21-Year High
Gary M. Owens, MD
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Approvals, News & Updates
FDA Approvals of Brand-Name Prescription Cancer Drugs in 2017
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Approvals, News & Updates
Alunbrig (Brigatinib) Approved for Metastatic NSCLC with ALK Mutation
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Approvals, News & Updates, Lung Cancer
Calquence (Acalabrutinib) Approved for Relapsed or Refractory Mantle-Cell Lymphoma in Adults
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Approvals, News & Updates, Lymphoma
Imbruvica (Ibrutinib) First Drug Approved Specifically for Marginal-Zone Lymphoma and for Chronic Graft-versus-Host Disease
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Approvals, News & Updates, Lymphoma
Imfinzi (Durvalumab) a New PD-L1 Inhibitor Approved for the Treatment of Advanced or Metastatic Urothelial Cancer
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Approvals, News & Updates, Bladder Cancer
Kisqali (Ribociclib): Second CDK4/CDK6 Inhibitor Approved for Postmenopausal Women with HR-Positive, HER2-Negative Advanced Breast Cancer
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Approvals, News & Updates, Breast Cancer
Last modified: October 30, 2017